Palatin Technologies Inc.

r. Spana, co-founder of Palatin, has been our chief executive officer and president since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly-held life science company. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.

Dr. Sharma is vice president and chief scientific officer at Palatin Technologies, Inc., and has been with the company since 1995. He is the inventor of Palatin's proprietary, MIDAS drug discovery platform. Dr. Sharma is a peptide chemist with more than 18 years of experience in the areas of peptide research, drug design and discovery. Prior to joining Palatin, Dr. Sharma was a research scientist in the research group of Prof. Victor J. Hruby, of the University of Arizona, Tucson from 1988 to 1994. From 1984 to 1988, Dr. Sharma was a scientist in the research group of Prof. Robert Schwyzer, of the Swiss Federal Institute of Technology, Zurich (ETH-Zurich), Switzerland. Dr. Sharma has several issued patents and patent applications pending and is the author of over 50 publications. He earned his Ph.D. in chemistry from the Central Drug Research Institute in Lucknow, India.

Dr. Hallam joined Palatin in May, 2005 as executive vice president of research & development. He possesses over 20 years of drug discovery and development experience within the pharmaceutical industry. From 1996 to 2005, Dr. Hallam held key senior management leadership positions within AstraZeneca R&D, including vice president of biologics based out of the UK, vice president of respiratory and inflammation research based in Sweden and vice president of medical affairs within the US. During this time, Dr. Hallam developed and implemented programs to broaden the firm’s portfolio of products, established strategic partner relationships and defined new discovery strategies. From 1985 to 1995, Dr. Hallam served at progressively senior management positions within Smith Kline & French Research, Glaxo Group Research and Roche Research. His accomplishments include development of numerous drug candidates for a variety of indications, including asthma, rheumatoid and osteo-arthritis, multiple sclerosis and transplant rejection. Dr. Hallam joined the pharmaceutical industry after a post-doctoral fellowship at the Physiological Laboratory, University of Cambridge, UK. He earned his Ph.D. in biochemistry from the University of London and his B.Sc. from the University of Leeds.

John Prendergast, Executive Chairman and CEO, is a biopharmaceutical executive who has been involved in the financing and corporate development of early to mid-stage biotechnology companies over the past 15 years. He is a co-inventor of Antyra's Phenogenix and Proteome Panning? technology modules. He is a co-founder and currently serves on the boards of Avigen Inc., Palatin Technologies and Avax Technologies. From 1991-1996, Dr. Prendergast was Managing Director of the Castle Group, a New York-based merchant bank where he was responsible for the identification and evaluation of products and technologies for the formation and development of a range of venture start-ups. He is currently the President of SummerCloud Bay Inc., a consulting practice specializing in these activities.

Mr. Hull has been a director since September 2005. Mr. Hull has over three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company in October 1987 and is currently Senior Vice President, Pharmaceuticals. Prior to his current position, he served in the R&D organization of GlaxoSmithKline as Vice President and Worldwide Director of Therapeutic Development and Product Strategy-Neurology and Psychiatry. Prior to that, he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome Inc. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.

Dr. Taber has been a director since May 2001. Dr. Taber began his career in the pharmaceutical industry in 1962, holding a succession of positions within Schering Corporation’s biological research group before leaving in 1982 as a director of biological research. He has also held a number of increasingly important positions with DuPont Pharmaceuticals and the DuPont Merck Pharmaceutical Company, including director of pharmaceutical research, director of pharmaceutical and biotechnology research, vice president of pharmaceutical research and vice president of extramural research and development. From 1994 to 1998, Dr. Taber held the position of senior vice president of research and development at Synaptic Pharmaceuticals Corporation before founding Message Pharmaceuticals, Inc. in 1998 serving as president and chief executive officer until 2000. Dr. Taber earned his Ph.D. in pharmacology from the Medical College of Virginia.